Report From International Hyperhidrosis Society..
“Late breaking news hit the European Academy of Dermatology and Venereology (EADV) conference in Vienna this month. TWO California-based companies, each currently developing new hyperhidrosis treatments released effectiveness results for their products.
DRM04 is a small-molecule topical (applied on top of the skin) anticholinergic for the treatment of underarm excessive sweating (hyperhidrosis) being developed by Dermira (Menlo Park, CA).
New clinical results show that patients treated for four weeks with DRM04 reported significant improvements in their hyperhidrosis-related quality-of-life compared to patients who received placebo.
THVD-102 is a combination oral treatment (taken twice per day by mouth) under development for BOTH primary and secondary hyperhidrosis by the company TheraVida of San Mateo, CA. It is the only oral, systemically-acting drug (working in the body as a whole) for hyperhidrosis currently in the works (that we know of).
THVD-102 includes both the oral medicine oxybutynin, (which is sometimes used to treat hyperhidrosis, but can have side effects like dry mouth that limit its long-term acceptability) and a delayed-release version of another oral med called pilocarpine. Pilocarpine works to combat oxybutynin’s side effects, including dry mouth.